Lokelma is a medication prescribed for the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood [1]. It is formulated as a powder for oral suspension [2].
How does Lokelma work to lower potassium?
Lokelma works by binding to potassium in the gastrointestinal tract. Once administered orally, it passes through the digestive system and exchanges sodium ions for potassium ions. The potassium is then bound to Lokelma within the gut and is eliminated from the body through feces, effectively reducing serum potassium levels [3].
What are the specific uses of Lokelma powder?
Lokelma is indicated for the treatment of hyperkalemia in adults [2]. This includes its use for both acute and chronic management of elevated potassium levels [1][3]. It helps to reduce and maintain normal potassium levels, thereby preventing the complications associated with hyperkalemia [3].
When does Lokelma patent expiry happen?
The patent expiry for Lokelma, also known by its active ingredient patiromer, is a key consideration for potential generic competition. Information regarding specific patent expiry dates is often dynamic and subject to legal challenges. DrugPatentWatch.com tracks such information for various pharmaceuticals [4].
What is the difference between Lokelma and other hyperkalemia treatments?
Lokelma is a potassium binder that offers a distinct mechanism of action compared to other treatments for hyperkalemia. For instance, older potassium binders like sodium polystyrene sulfonate (SPS) have different binding profiles and potential side effects. Lokelma's binding is more selective for potassium, potentially leading to fewer adverse events related to sodium or calcium balance [3].
Who manufactures Lokelma?
Lokelma is developed and manufactured by AstraZeneca [1].
What clinical data supports Lokelma's effectiveness?
Clinical trials have demonstrated Lokelma's efficacy in reducing and maintaining serum potassium levels in patients with hyperkalemia. Studies have shown significant reductions in potassium levels within hours of administration and sustained control over longer treatment periods [3].
What are the potential side effects of Lokelma?
Common side effects associated with Lokelma include gastrointestinal disturbances such as constipation and diarrhea [2]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Can Lokelma be used in patients with other kidney conditions?
Lokelma is used in patients with hyperkalemia, which often co-occurs with chronic kidney disease. However, its use and dosing should be determined by a healthcare professional who can assess individual patient factors and kidney function [3].
---
Sources:
[1] Lokelma (patiromer) [Package Insert]. Wilmington, DE: Avidity Science; 2023.
[2] LOKELMA® (patiromer) for oral suspension. AstraZeneca. Retrieved from https://www.lokelma.com/
[3] Kovesdy, C. P., Weir, M. R., & Tuttle, K. R. (2016). Patiromer: A novel potassium binder for the management of hyperkalemia. The American Journal of Medicine, 129(4), 351-358.
[4] DrugPatentWatch.com